Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydromorphone + morphine is a combination of two potent opioid analgesics used for the management of moderate to severe pain. Both drugs act primarily as agonists at the mu-opioid receptor, leading to analgesia, sedation, and euphoria. Hydromorphone is significantly more potent than morphine—approximately 2–8 times greater by some estimates and up to 20 times more potent parenterally—requiring careful dose adjustment when switching between these agents[2][3]. Morphine serves as the standard comparator for opioid efficacy in clinical practice[3][4]. Both drugs can cause respiratory depression, constipation, nausea, and have a high potential for abuse and dependence[1][5]. They are typically reserved for cases where non-opioid analgesics are insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydromorphone + morphine.